Dangers of Making Health Claims in CBD Product Labelling
One question that we get a lot about industrial hemp and CBD products is how to navigate the requirements of The Food and Drug Administration. One area where you can definitely get into trouble with the FDA is by making health claims about a CBD product on your label.
The FDA has sent warning letters to companies that have made health claims about the effects of CBD on the human body. This is one area where the FDA is definitely taking action. We have not seen the FDA take action about CBD in general but they will pursue you for health claims on your label.
We help CBD companies every day navigate FDA requirements and other federal laws about CBD. Please call us if you have any questions.
Related Article
Psychedelic Therapy & Law Update – April 2026
President Trump to Issue Executive Order on Ibogaine President Trump will sign an executive order opening doors for more federal reserach on ibogaine, the naturally occuring psychedelic substance with indigenous roots in Africa. For more information, see this article by clicking here. Ibogaine has shown significant benefits for veterans suffering from war trauma, those suffering from […]
Psychedelic Therapy & Law Update – March 2026
Colorado starts the rulemaking process again for NMHA program changes DOR Natural Medicine Division is proposing several rules changes to the NMHA rules. These proposed changes include a significant increase in the cost of standard healing center licenses (from $6k to over $10k). Other proposed changes include adding an owner entity fee, prohibiting cultivator sampling […]
Psychedelic Therapy & Law Update – February 2026
Maryland and New Jersey moving toward creation of psilocybin programs The Maryland Task Force on Responsible Use of Natural Psychedelic Substances, in a report near the end of 2025 endorsed the creation of a regulated psilocybin program in the state. The recommendation still needs to be adopted by the Maryland legislature, but this is an […]